Bioinformatics software provider Qlucore, Lund, Sweden, is expanding its business into precision medicine and precision diagnostics. In order to finance the expansion Qlucore has recently finalized a rights issue of €400,000. The company has also announced two new members of its board.

Carl-Johan Ivarsson, Qlucore.

Carl-Johan Ivarsson, Qlucore.

Qlucore has created a software platform for precision medicine and diagnostics, building on its Qlucore Omics Explorer, now used by researchers in more than 35 countries. The first generation of the new software platform supports analysis and visualization of so-called fusion genes that play important roles in the diagnosis and treatment of cancer forms, such as acute lymphoblastic leukemia and non-small cell lung cancer. Future versions will include classifiers that will help physicians and pathologists to classify a sample in subgroups using gene expression signatures.

Data generated with next-generation sequencing (NGS) technologies are increasingly being used in clinical settings. “It is a natural development that the data that our research customers have worked with using Qlucore Omics Explorer for several years is now ready to be moved into clinical use,” says Carl-Johan Ivarsson, president of Qlucore. “The lack of software solutions is apparent, and with our experience we will fill that gap.”

Qlucore has appointed Johan Thiel and Boel Sundvall to the board. Thiel is an entrepreneur with a passion for building business and creating value; for the past 6 years he has been a CEO focusing on sales and marketing, manufacturing, and product development. Boel has a master’s degree in business and economics from the Stockholm School of Economics and has held senior management positions in several companies listed in Sweden. She has broad experience in several industries, with a background in finance, corporate finance, investor relations, and communications.

For more information, visit Qlucore.